Piramal Pharma (NSE:PPLPHARMA) EBIT per Share : ₹6.11 (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma EBIT per Share?

Piramal Pharma's EBIT per Share for the three months ended in Dec. 2024 was ₹1.39. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was ₹6.11.

During the past 12 months, the average EBIT per Share Growth Rate of Piramal Pharma was 102.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Piramal Pharma's EBIT per Share or its related term are showing as below:

NSE:PPLPHARMA's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 8.3
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Piramal Pharma's EBIT for the three months ended in Dec. 2024 was ₹1,701 Mil.

Piramal Pharma EBIT per Share Historical Data

The historical data trend for Piramal Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma EBIT per Share Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

EBIT per Share

5.54

1.79

4.88

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial										0.99	2.54	0.47	1.71	1.39

Piramal Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Piramal Pharma's EBIT per Share for the fiscal year that ended in Mar. 2024 is calculated as

	EBIT per Share		(A: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	6262.4	/	1283.510
=	4.88

Piramal Pharma's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1701.1	/	1226.667
=	1.39

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6.11

Piramal Pharma (NSE:PPLPHARMA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Piramal Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » EBIT per Share

Traded in Other Exchanges

543635:India

Address

Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramalpharma.com

Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.

Piramal Pharma Headlines

No Headlines